

## Contents

|                                                                          |             |  |  |
|--------------------------------------------------------------------------|-------------|--|--|
| <b>Preface</b>                                                           | <i>xi</i>   |  |  |
| <b>Acknowledgments</b>                                                   | <i>xiii</i> |  |  |
| <b>About the Companion Website</b>                                       | <i>xv</i>   |  |  |
| <b>1 Introduction</b>                                                    | <b>1</b>    |  |  |
| 1.1 The Basics of Molecular Medicine                                     | 2           |  |  |
| 1.1.1 Topics of Molecular Medicine                                       | 2           |  |  |
| 1.1.2 Stages of Drug Development                                         | 3           |  |  |
| 1.2 The Human Cell                                                       | 4           |  |  |
| 1.2.1 Organelles                                                         | 5           |  |  |
| 1.2.1.1 The Nucleus                                                      | 5           |  |  |
| 1.2.1.2 Mitochondria                                                     | 6           |  |  |
| 1.2.1.3 Endoplasmic Reticulum and Golgi Apparatus                        | 7           |  |  |
| 1.2.1.4 Peroxisome and Lysosome                                          | 8           |  |  |
| 1.2.2 Cell Cycle                                                         | 8           |  |  |
| 1.2.3 Apoptosis                                                          | 9           |  |  |
| 1.3 DNA Replication and Gene Expression                                  | 10          |  |  |
| 1.3.1 DNA Replication                                                    | 11          |  |  |
| 1.3.2 Mutations                                                          | 13          |  |  |
| 1.3.3 Transcription                                                      | 14          |  |  |
| 1.3.4 Epigenetic Regulation of Gene Expression                           | 19          |  |  |
| 1.3.5 Translation                                                        | 22          |  |  |
| 1.3.6 Protein Degradation                                                | 25          |  |  |
| 1.4 Biological Communication                                             | 26          |  |  |
| 1.4.1 Neurotransmitters                                                  | 26          |  |  |
| 1.4.2 Hormones                                                           | 28          |  |  |
| 1.4.3 Signal Transduction                                                | 28          |  |  |
| 1.5 The Immune System                                                    | 31          |  |  |
| 1.5.1 The Innate Immune System                                           | 32          |  |  |
| 1.5.1.1 The Complement System                                            | 33          |  |  |
| 1.5.2 The Adaptive Immune System                                         | 34          |  |  |
| 1.5.2.1 Cellular Immunity                                                | 34          |  |  |
| 1.5.2.2 Humoral Immunity                                                 | 35          |  |  |
| References                                                               | 37          |  |  |
| <b>2 Methods in Molecular Medicine</b>                                   | <b>41</b>   |  |  |
| 2.1 DNA Microarrays                                                      | 42          |  |  |
| 2.2 Quantitative Polymerase Chain Reaction                               | 45          |  |  |
| 2.2.1 Basic Principles of Conventional PCR and Reverse-transcription PCR | 46          |  |  |
| 2.2.2 Basic Principle of Real-time PCR                                   | 47          |  |  |
| 2.2.3 Reporter Dyes and Fluorescent Reporter Probes                      | 48          |  |  |
| 2.3 Next-generation Sequencing                                           | 51          |  |  |
| 2.3.1 Second-generation Sequencing                                       | 52          |  |  |
| 2.3.2 Third-generation Sequencing                                        | 55          |  |  |
| 2.3.3 Exome Sequencing                                                   | 56          |  |  |
| 2.3.4 RNA-Seq and Single-cell Sequencing                                 | 57          |  |  |
| 2.4 Proteomics                                                           | 58          |  |  |
| 2.4.1 Two-dimensional Gel Electrophoresis and Mass Spectrometry          | 59          |  |  |
| 2.4.2 Quantitative and Shotgun Proteomics                                | 62          |  |  |
| 2.4.3 Elucidation of Protein Structures                                  | 64          |  |  |
| 2.5 Animal Models in Biomedical Research                                 | 65          |  |  |
| 2.6 Alternatives to Animal Testing                                       | 68          |  |  |
| 2.6.1 3D Cell Culture, Spheroids, and Organoids                          | 69          |  |  |
| 2.6.2 Bioprinting                                                        | 70          |  |  |
| 2.6.3 Organ-on-a-Chip                                                    | 72          |  |  |
| 2.6.4 Replacement of Animal Components in Biomedical Research            | 73          |  |  |
| 2.7 Additional Methods                                                   | 74          |  |  |
| 2.7.1 Fluorescence Microscopy                                            | 74          |  |  |
| 2.7.2 Flow Cytometry and Fluorescence-activated Cell Sorting             | 76          |  |  |
| 2.7.3 Surface Plasmon Resonance                                          | 76          |  |  |
| References                                                               | 77          |  |  |
| <b>3 Genetic Disorders</b>                                               | <b>81</b>   |  |  |
| 3.1 Single-gene Disorders                                                | 82          |  |  |
| 3.1.1 Autosomal Dominant Disorders                                       | 85          |  |  |
| 3.1.1.1 Familial Hypercholesterolemia                                    | 85          |  |  |
| 3.1.1.2 Polycystic Kidney Disease                                        | 87          |  |  |
| 3.1.1.3 Marfan's Syndrome                                                | 88          |  |  |
| 3.1.1.4 Huntington's Disease                                             | 88          |  |  |
| 3.1.2 Autosomal Recessive Disorders                                      | 90          |  |  |
| 3.1.2.1 Cystic Fibrosis                                                  | 90          |  |  |
| 3.1.2.2 Tay-Sachs Disease                                                | 92          |  |  |
| 3.1.2.3 Phenylketonuria                                                  | 93          |  |  |
| 3.1.2.4 Xeroderma Pigmentosum                                            | 95          |  |  |
| 3.1.3 X-linked Recessive Disorders                                       | 96          |  |  |

|          |                                                 |            |          |                                                          |            |
|----------|-------------------------------------------------|------------|----------|----------------------------------------------------------|------------|
| 3.1.3.1  | Red–Green Color Blindness                       | 96         | 5.3.5    | Indirect ELISA                                           | 160        |
| 3.1.3.2  | Duchenne and Becker Muscular Dystrophy          | 97         | 5.3.6    | Rapid Antigen Test                                       | 160        |
| 3.1.4    | Mitochondriopathies                             | 98         | 5.3.7    | Polymerase Chain Reaction                                | 161        |
| 3.2      | Polygenic Disorders                             | 101        | 5.3.8    | Next-generation Sequencing                               | 162        |
| 3.2.1    | Asthma                                          | 102        | 5.3.9    | Antiviral Susceptibility Testing                         | 163        |
| 3.2.2    | Diabetes Mellitus                               | 103        | 5.4      | Antiviral Therapy                                        | 163        |
|          | References                                      | 105        | 5.4.1    | Human Immunodeficiency Virus                             | 167        |
| <b>4</b> | <b>Molecular Oncology</b>                       | <b>109</b> | 5.4.2    | Hepatitis C Virus                                        | 170        |
| 4.1      | Basics of Oncology                              | 110        | 5.4.3    | Influenza Virus                                          | 171        |
| 4.1.1    | Oncogenes and Tumor Suppressor Genes            | 110        | 5.4.4    | Other Viruses                                            | 172        |
| 4.1.2    | Hallmarks of Cancer                             | 111        | 5.5      | Prions                                                   | 172        |
| 4.1.3    | Treatment Options for Cancer                    | 111        |          | References                                               | 173        |
| 4.2      | Selected Cancer Diseases                        | 112        | <b>6</b> | <b>Bacteria and Eukaryotic Pathogens</b>                 | <b>177</b> |
| 4.2.1    | Breast Cancer                                   | 112        | 6.1      | Bacteria                                                 | 178        |
| 4.2.2    | Lung Cancer                                     | 114        | 6.1.1    | Virulence Factors                                        | 180        |
| 4.2.3    | Hepatocellular Carcinoma                        | 116        | 6.1.2    | Serotypes                                                | 182        |
| 4.2.4    | Colorectal Cancer                               | 117        | 6.1.3    | Examples of Bacterial Diseases                           | 182        |
| 4.2.5    | Prostate Cancer                                 | 120        | 6.1.3.1  | Tuberculosis                                             | 182        |
| 4.2.6    | Hematological Malignancies                      | 123        | 6.1.3.2  | Pneumonia                                                | 183        |
| 4.2.6.1  | Leukemia                                        | 124        | 6.1.3.3  | Cholera                                                  | 184        |
| 4.2.6.2  | Further Hematological Malignancies              | 126        | 6.1.4    | Biofilms                                                 | 184        |
| 4.3      | Oncolytic Virus Therapy                         | 127        | 6.1.5    | Bacterial Vaccines, Diagnostic Methods, and Antibiotics  | 184        |
| 4.4      | Cancer Stem Cells                               | 128        | 6.1.5.1  | Vaccines                                                 | 184        |
| 4.5      | Cancer Immunotherapy                            | 130        | 6.1.5.2  | Diagnostic Methods                                       | 185        |
| 4.5.1    | CAR-T Cell Therapy                              | 130        | 6.1.5.3  | Antibiotics                                              | 186        |
| 4.5.2    | Immune Checkpoint Inhibitors                    | 132        | 6.2      | Eukaryotic Pathogens                                     | 192        |
| 4.5.3    | mRNA Cancer Vaccines                            | 134        | 6.2.1    | Fungi                                                    | 192        |
|          | References                                      | 135        | 6.2.2    | Protozoan Parasites                                      | 193        |
| <b>5</b> | <b>Molecular Virology</b>                       | <b>139</b> | 6.2.2.1  | <i>Plasmodium falciparum</i> (Malaria)                   | 193        |
| 5.1      | The Basics of Virology                          | 140        | 6.2.3    | Metazoan Parasites                                       | 195        |
| 5.1.1    | Human Immunodeficiency Virus                    | 143        |          | References                                               | 196        |
| 5.1.2    | Severe Acute Respiratory Syndrome Coronavirus 2 | 146        | <b>7</b> | <b>Genomics</b>                                          | <b>199</b> |
| 5.1.3    | Hepatitis B Virus                               | 147        | 7.1      | Whole Genome Sequencing                                  | 200        |
| 5.1.4    | Influenza Virus                                 | 148        | 7.1.1    | Cloning of DNA                                           | 200        |
| 5.2      | Vaccination                                     | 149        | 7.1.2    | Sequencing of Genomes                                    | 200        |
| 5.2.1    | Live Vaccines                                   | 151        | 7.2      | The Human Genome                                         | 202        |
| 5.2.1.1  | Attenuated Virus Vaccines                       | 151        | 7.2.1    | Sequencing of the Human Genome                           | 202        |
| 5.2.1.2  | Recombinant Virus Vaccines                      | 154        | 7.2.2    | Interpretation of the Human Genome                       | 204        |
| 5.2.2    | Nonliving Vaccines                              | 154        | 7.2.3    | Sequencing of Individual Human Genomes                   | 208        |
| 5.2.2.1  | Inactivated Virus Vaccines                      | 154        | 7.3      | Sequencing of Ancient DNA                                | 209        |
| 5.2.2.2  | Subunit Vaccines                                | 155        | 7.3.1    | The Neanderthal Genome Project                           | 209        |
| 5.2.2.3  | DNA Vaccines                                    | 156        | 7.4      | Follow-up Initiatives of the Human Genome Project        | 211        |
| 5.2.2.4  | mRNA Vaccines                                   | 156        | 7.4.1    | The International HapMap Project                         | 211        |
| 5.2.3    | HIV Vaccines                                    | 159        | 7.4.2    | The 1000 Genomes Project and the Personal Genome Project | 212        |
| 5.3      | Detection of Viruses                            | 159        | 7.4.3    | Encyclopedia of DNA Elements (ENCODE)                    | 212        |
| 5.3.1    | Cytopathic Effects                              | 159        | 7.4.4    | Further Genomic Projects                                 | 214        |
| 5.3.2    | Electron Microscopy                             | 159        |          | References                                               | 216        |
| 5.3.3    | Hemagglutination Assay                          | 160        |          |                                                          |            |
| 5.3.4    | Enzyme-linked Immunosorbent Assay               | 160        |          |                                                          |            |

|           |                                                             |            |  |  |  |
|-----------|-------------------------------------------------------------|------------|--|--|--|
| <b>8</b>  | <b>Genetic Testing</b>                                      | <b>219</b> |  |  |  |
| 8.1       | Types of Genetic Tests                                      | 220        |  |  |  |
| 8.1.1     | Postnatal Genetic Tests                                     | 220        |  |  |  |
| 8.1.2     | Prenatal Genetic Tests                                      | 222        |  |  |  |
| 8.2       | Chromosome Abnormalities                                    | 224        |  |  |  |
| 8.2.1     | Conventional Karyotyping                                    | 225        |  |  |  |
| 8.2.2     | Fluorescence In Situ Hybridization                          | 225        |  |  |  |
| 8.2.3     | Comparative Genomic Hybridization                           | 228        |  |  |  |
| 8.2.4     | Optical Genome Mapping                                      | 229        |  |  |  |
| 8.3       | Molecular Diagnosis                                         | 229        |  |  |  |
| 8.3.1     | PCR-based Methods                                           | 229        |  |  |  |
| 8.3.2     | DNA Microarray-based Methods                                | 232        |  |  |  |
| 8.3.3     | DNA Sequencing                                              | 234        |  |  |  |
|           | References                                                  | 236        |  |  |  |
| <b>9</b>  | <b>Pharmacogenetics/Pharmacogenomics</b>                    | <b>239</b> |  |  |  |
| 9.1       | Uptake and Transport of Drugs                               | 242        |  |  |  |
| 9.2       | Drug Metabolism                                             | 242        |  |  |  |
| 9.2.1     | Cytochrome P450 Enzymes                                     | 243        |  |  |  |
| 9.2.2     | Other Drug-metabolizing Enzymes                             | 246        |  |  |  |
| 9.3       | Drug Targeting                                              | 247        |  |  |  |
| 9.4       | Drug Toxicity and Hypersensitivity                          | 250        |  |  |  |
| 9.5       | Drug Development and Individual Pharmacotherapy             | 250        |  |  |  |
|           | References                                                  | 252        |  |  |  |
| <b>10</b> | <b>Recombinant Protein Drugs</b>                            | <b>255</b> |  |  |  |
| 10.1      | Production of Recombinant Proteins                          | 258        |  |  |  |
| 10.1.1    | Bacteria                                                    | 259        |  |  |  |
| 10.1.2    | Yeast and Other Fungi                                       | 260        |  |  |  |
| 10.1.3    | Insect Cells                                                | 261        |  |  |  |
| 10.1.4    | Mammalian Cells                                             | 261        |  |  |  |
| 10.1.5    | Transgenic Animals and Plants                               | 262        |  |  |  |
| 10.2      | Classes of Recombinant Drugs                                | 264        |  |  |  |
| 10.2.1    | Monoclonal Antibodies                                       | 265        |  |  |  |
| 10.2.2    | Hormones                                                    | 272        |  |  |  |
| 10.2.3    | Growth Factors                                              | 275        |  |  |  |
| 10.2.4    | Fusion Proteins                                             | 277        |  |  |  |
| 10.2.5    | Cytokines                                                   | 278        |  |  |  |
| 10.2.6    | Blood Coagulation Factors: Anticoagulants and Thrombolytics | 279        |  |  |  |
| 10.2.7    | Therapeutic Enzymes                                         | 281        |  |  |  |
| 10.2.8    | Recombinant Vaccines                                        | 282        |  |  |  |
|           | References                                                  | 283        |  |  |  |
| <b>11</b> | <b>Gene Therapy</b>                                         | <b>287</b> |  |  |  |
| 11.1      | Types of Gene Therapy                                       | 288        |  |  |  |
| 11.2      | Methods of Gene Transfer                                    | 289        |  |  |  |
| 11.2.1    | Retroviral Vectors                                          | 290        |  |  |  |
| 11.2.2    | Adenoviral Vectors                                          | 292        |  |  |  |
| 11.2.3    | Adeno-associated Virus Vectors                              | 293        |  |  |  |
| 11.2.4    | Nonviral Gene Transfer                                      | 295        |  |  |  |
| 11.3      | Tissue Specificity of Gene Transfer and Gene Expression     | 297        |  |  |  |
| 11.4      | Applications of Gene Therapy                                | 300        |  |  |  |
| 11.4.1    | Gene Therapy of Monogenic Diseases                          | 300        |  |  |  |
| 11.4.2    | Gene Therapy of Cancer                                      | 303        |  |  |  |
| 11.4.3    | Other Diseases                                              | 305        |  |  |  |
| 11.5      | Genome Editing with CRISPR/Cas                              | 305        |  |  |  |
| 11.6      | Future Prospects                                            | 309        |  |  |  |
|           | References                                                  | 309        |  |  |  |
| <b>12</b> | <b>Stem Cells</b>                                           | <b>313</b> |  |  |  |
| 12.1      | Embryonic Stem Cells                                        | 315        |  |  |  |
| 12.1.1    | Generation and Properties of Embryonic Stem Cells           | 315        |  |  |  |
| 12.1.2    | Therapeutic Cloning                                         | 317        |  |  |  |
| 12.2      | Adult Stem Cells                                            | 318        |  |  |  |
| 12.3      | Induced Pluripotent Stem Cells                              | 320        |  |  |  |
| 12.3.1    | Generation of Induced Pluripotent Stem Cells                | 320        |  |  |  |
| 12.3.2    | Properties of Induced Pluripotent Stem Cells                | 323        |  |  |  |
| 12.4      | Transdifferentiation and Direct Reprogramming               | 323        |  |  |  |
| 12.5      | Differentiation of Stem Cells                               | 325        |  |  |  |
| 12.6      | Medical Applications of Stem Cells                          | 328        |  |  |  |
| 12.6.1    | Adult Stem Cell Therapies                                   | 328        |  |  |  |
| 12.6.2    | Pluripotent Stem Cells for Biomedical Research              | 330        |  |  |  |
| 12.6.3    | Therapeutic Applications of Pluripotent Stem Cells          | 333        |  |  |  |
| 12.6.3.1  | Applications in the Central Nervous System                  | 334        |  |  |  |
| 12.6.3.2  | Applications in the Eye                                     | 335        |  |  |  |
| 12.6.3.3  | Diabetes                                                    | 335        |  |  |  |
| 12.6.3.4  | Heart Disease                                               | 336        |  |  |  |
| 12.6.3.5  | Combinations of Stem Cell and Gene Therapy                  | 337        |  |  |  |
|           | References                                                  | 338        |  |  |  |
| <b>13</b> | <b>Oligonucleotide-based Strategies</b>                     | <b>341</b> |  |  |  |
| 13.1      | Antisense Oligonucleotides (ASOs) and Ribozymes             | 343        |  |  |  |
| 13.1.1    | Mechanism of Action of ASOs                                 | 344        |  |  |  |
| 13.1.2    | Development and Stabilization of ASO                        | 345        |  |  |  |
| 13.1.3    | Clinical Applications of ASO                                | 347        |  |  |  |
| 13.1.4    | Ribozymes                                                   | 350        |  |  |  |
| 13.2      | RNA Interference                                            | 351        |  |  |  |
| 13.2.1    | Mechanism of RNAi                                           | 352        |  |  |  |
| 13.2.2    | Nonspecific Side Effects                                    | 355        |  |  |  |
| 13.2.3    | Stabilization and Delivery                                  | 356        |  |  |  |
| 13.2.4    | Research and Preclinical Applications of RNAi               | 357        |  |  |  |
| 13.2.5    | Clinical Applications of RNAi                               | 358        |  |  |  |
| 13.3      | MicroRNAs                                                   | 361        |  |  |  |

|          |                                                                          |     |
|----------|--------------------------------------------------------------------------|-----|
| 13.3.1   | The Biology of MicroRNAs                                                 | 361 |
| 13.3.2   | MicroRNAs and Disease                                                    | 363 |
| 13.3.3   | MicroRNA-Based Drugs in Clinical Development                             | 366 |
| 13.4     | Aptamers, Decoy Oligonucleotides, and Immunostimulatory Oligonucleotides | 367 |
| 13.4.1   | Aptamers                                                                 | 368 |
| 13.4.1.1 | Selection of Aptamers                                                    | 368 |
| 13.4.1.2 | Modifications of Aptamers                                                | 371 |
| 13.4.1.3 | Clinical Development of Aptamers                                         | 373 |
| 13.4.2   | Decoy Oligonucleotides                                                   | 375 |
| 13.4.3   | Immunostimulatory Oligonucleotides                                       | 376 |
|          | References                                                               | 377 |

|           |                                             |            |
|-----------|---------------------------------------------|------------|
| <b>14</b> | <b>Ethics in Molecular Medicine</b>         | <b>383</b> |
| 14.1      | The Basis of Bioethics                      | 384        |
| 14.2      | Fields of Application                       | 386        |
| 14.2.1    | Genetic Testing and the “Right Not to Know” | 386        |
| 14.2.2    | Stem Cell Research                          | 388        |
| 14.2.3    | Preimplantation Genetic Diagnosis           | 390        |
| 14.2.4    | Animal Experimentation                      | 393        |

|                      |            |
|----------------------|------------|
| <b>Abbreviations</b> | <b>399</b> |
|----------------------|------------|

|                 |            |
|-----------------|------------|
| <b>Glossary</b> | <b>405</b> |
|-----------------|------------|

|              |            |
|--------------|------------|
| <b>Index</b> | <b>409</b> |
|--------------|------------|